◆ Latest: Retatrutide Phase 3 trial reports 24% weight reduction at 48 wks◆ Established: 10 peptides now FDA approved for metabolic indications◆ Preclinical: BPC-157 meta-analysis (17 rodent studies) published◆ Evidence: new mitochondrial peptide review covers MOTS-c, SS-31, Humanin◆ Safety: hCG supply disruption update, Q2 2026◆ Editorial: The Mitochondrial Decade, new long-read◆ Latest: Retatrutide Phase 3 trial reports 24% weight reduction at 48 wks◆ Established: 10 peptides now FDA approved for metabolic indications◆ Preclinical: BPC-157 meta-analysis (17 rodent studies) published◆ Evidence: new mitochondrial peptide review covers MOTS-c, SS-31, Humanin◆ Safety: hCG supply disruption update, Q2 2026◆ Editorial: The Mitochondrial Decade, new long-read

Definition

Compounding (503A)

Section 503A of the FD&C Act allows state-licensed pharmacies to prepare custom formulations for individual patients. The FDA maintains a Negative List of bulk substances that cannot be used under 503A.

Browse the full glossary

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.